Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
An Industry Built on Debt
Real estate has long been the stimulus behind China's rapid economic development. House-buying became an investment as prices soared, thus resulting in overbuild. Evergrande's downfall signals the halt on China's reliance on its real estate sector as the country seeks to regulate and strengthen the economy and its foundation.
Nov 08, 2021 09:42 AM
The Development of China's New Generation Information Technology
Sep 21, 2023 11:46 PM
An Entrepreneur and Her New Journey to Globalization
Sep 21, 2023 05:40 PM
EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part I）
Sep 21, 2023 04:43 PM
Robooter: Structuring New Ecology for Elderly Care
Sep 20, 2023 06:17 PM